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Background: Persistent systemic infection results in excessive trafficking of peripheral immune cells into the central
nervous system (CNS), thereby contributing to sustained neuroinflammation that leads to neurocognitive deficits. In
this study, we explored the role of opportunistic systemic infection with Streptococcus pneumoniae in the
recruitment of peripheral leukocytes into the CNS and its contribution to HIV-1-associated neurocognitive
disorders in opioid-dependent individuals.
Methods: Wild-type B6CBAF1 (wt), μ-opioid receptor knockout (MORKO), FVB/N luciferase transgenic, and Toll-like
receptor 2 and 4 knockout (TLR2KO and TLR4KO) mice were subcutaneously implanted with morphine/placebo pellet
followed by HIV-1 Transactivator of transcription (Tat) protein injection intravenously and S. pneumoniae administration
intraperitoneally. On postoperative day 5, brains perfused with phosphate-buffered saline were harvested and subjected
to immunohistochemistry (for bacterial trafficking and chemokine ligand generation), flow cytometry (for phenotypic
characterization of CNS trafficked immune cells), Western blot, and real-time PCR (for ligand expression).
Results: Our results show differential leukocyte trafficking of T lymphocytes (CD3+) and inflammatory monocytes (Ly6C+)
into the CNS of mice treated with morphine, HIV-1 Tat, and/or S. pneumoniae. In addition, we demonstrate a
Trojan horse mechanism for bacterial dissemination across the blood-brain barrier into the CNS by monocytes.
Activation of TLRs on microglia induced a chemokine gradient that facilitated receptor-dependent trafficking of
peripheral immune cells into the CNS. HIV-1 Tat induced trafficking of Ly6C+ and CD3+ cells into the CNS; infection
with S. pneumoniae facilitated infiltration of only T lymphocytes into the CNS. We also observed differential chemokine
secretion in the CNS, with CCL5 being the predominant chemokine following HIV-1 Tat treatment, which was
potentiated further with morphine. S. pneumoniae alone led to preferential induction of CXCL12. Furthermore, we
attributed a regulatory role for TLRs in the chemokine-mediated trafficking of leukocytes into the CNS. Chronic
morphine and HIV-1 Tat, in the context of systemic S. pneumoniae co-infection, differentially modulated induction
of TLR2/4, which consequently facilitated trafficking of TLR2→ CD3 + CCR5+ and TLR4→ Ly6C+(CCR5+/CXCR4+)
immune cells into the CNS.
Conclusion: Our murine study suggests that secondary infection in opioid-dependent individuals infected with
HIV-1 augments peripheral leukocyte trafficking as a consequence of sustained chemokine gradients in the CNS.
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The prevalence of HIV-associated neurocognitive disorders
(HAND) is on the rise because of longer survival rates
resulting from antiretroviral therapy. These effects are more
predominant in HIV-1-infected opioid-dependent individ-
uals [1–4]. Furthermore, due to their immunosuppressive
state, the incidence of systemic co-infection with opportun-
istic pathogens is also significantly higher in these patients.
Frequent and repeated systemic infection in various neuro-
degenerative diseases, such as Alzheimer’s and Parkinson’s
disease, results in unregulated activation of proinflamma-
tory cytokines in the central nervous system (CNS) leading
to progressive decline in cognitive function [5, 6]. Despite a
significant body of literature documenting the association
of recurrent systemic infection with increased neurocogni-
tive deficits, its role in the prevalence of HAND in opioid-
dependent individuals infected with HIV-1 has not been
delineated.
Peripheral leukocyte migration into the CNS contributes
to pathogenesis of inflammatory neurologic responses
during systemic infection [7, 8] through induction of che-
mokines and their receptors. In the current study, we
explored the contribution of specific chemokine receptors,
i.e., CXCR4 and CCR5, in differential leukocyte trafficking
into the CNS of mice following chronic morphine, HIV-1
Transactivator of transcription (Tat) protein, and/or co-
infection with Streptococcus pneumoniae. CCR5 and
CXCR4 are the predominant co-receptors that interact
with CD4+ T cells for HIV-1 entry into host cells [9].
Additionally, various independent studies have shown
that μ-opioid receptor (MOR) agonists, including mor-
phine, exacerbate the expression of CXCR4 and CCR5
on peripheral immune cells, as well as on microglial
cells, thereby increasing HIV-1 infectivity [10–14].
Toll-like receptors (TLRs) on various immune cells
recognize conserved motifs expressed by pathogens and
play an important role in recruiting leukocytes to the
sites of infection [15–17]. Unregulated TLR activation
has been implicated in HIV-1 pathogenesis [18, 19]. We
also previously showed that TLR activation on microglial
cells results in significant neuronal apoptosis in a HIV-1
Tat model with co-infection of S. pneumoniae in opioid-
dependent mice [20]. In the present study, we expanded
our previous observations to further investigate the role
of TLR-mediated CNS leukocyte trafficking as a contrib-
uting mechanism for HAND following chronic exposure
to morphine in a co-infection murine model.
We demonstrated, in a murine model, morphine treat-
ment in the context of HIV-1 Tat and S. pneumoniae or-
chestrate the migration of T cells through induction of
chemokine ligands CXCL12 and CCL5. Furthermore, we
attribute a specific role for TLR2 and TLR4 in the
chemokine-mediated leukocyte trafficking into the CNS.
In summary, secondary bacterial co-infection in a murinemodel of HIV-1 infection and drug abuse exacerbated per-
ipheral immune cell trafficking, thus disrupting neuroim-
mune homeostasis, thereby contributing to HAND.
Materials and methods
Experimental animal
Experiments were conducted on 8- to 12-week-old male
mice. Wild-type B6CBAF1 (wt), μ-opioid receptor knock-
out (MORKO), FVB/N luciferase transgenic, and Toll-like
receptor 2 and 4 knockout (TLR2KO and TLR4KO) mice
were obtained from Jackson Laboratory (Bar Harbor, ME)
and maintained in pathogen-free animal housing facilities
with a constant temperature (22 ± 1 °C) and humidity
(50 %) and with a regulated 12-h light/dark cycle. Animals
were housed three mice per cage and given standard food
and tap water ad libitum. Animal studies were approved
by the Institutional Animal Care and Use Committee at
the University of Minnesota. All procedures are in agree-
ment with the guidelines set forth by the National Insti-
tutes of Health’s Guide for the Care and Use of Laboratory
Animals.
Treatment
Mice were treated according to the procedure explained
in our previously published paper with slight modifica-
tion [20]. Briefly, mice anesthetized with isoflurane
(Halocarbon Products Corp., River Edge, NJ) were sub-
cutaneously implanted either with placebo or with a
slow-release morphine (25 mg, NIDA, Rockville, MD)
pellet (blood levels are 0.9–1.6 μg/ml at steady state)
and then injected intravenously (i.v.) with recombinant
full-length HIV-1 Tat protein (82 aa, Immunodiagnostic
Systems Inc., Gaithersburg, MD) with a dose of 10 μg/kg
[20–22]. To model an opportunistic infection in these
mice, animals were inoculated intraperitoneally (i.p.) with S.
pneumoniae serotype 3 strain (American Type Culture Col-
lection, ATTC 6303, Manassas, VA) with a dose of 1 × 103
colony-forming units (CFUs) in phosphate-buffered saline
(PBS; 0.01 M, 500 μl) 24 h following morphine treatment.
Five days following infection, animals were sacrificed and
tissues were harvested for ex vivo analysis.
Bioluminescence imaging and bacterial translocation
Morphine- or placebo-treated mice were inoculated in-
traperitoneally with luciferase-tagged S. pneumoniae sero-
type 3 (Xen10, Xenogen Corporation, Alameda, CA) at a
dose of 1 × 103 CFUs/500 μl PBS in the presence or absence
of HIV-1 Tat protein. At day 5, in live animals, bacterial
clearance and dissemination into the CNS were imaged
using Xenogen’s IVIS CCD camera system [23]. Total pho-
ton emission from selected and defined areas within the
images of each mouse was quantified as photons/s/cm2
using Living Image (Xenogen) and Igor (WaveMetrics,
Lake Oswego, OR) image analysis software.
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To measure luciferase activity in brain tissues, we used a
luminometer (TD-20/20, Turner Designs Inc., Sunnyvale,
CA). Animals were placed under gas anesthesia using iso-
flurane (2–2.5 %) and cardially perfused with ice-cold PBS
(0.01 M). After perfusion, animals were sacrificed and
PBS-perfused brains were aseptically removed and ho-
mogenized in lysis buffer (Promega Corporation, Madison,
WI). After centrifugation at 10,000 g for 10 min, the
supernatant of the brain lysate was collected and mixed
with the substrate luciferin (1:4; Promega Corporation);
luminescence was measured for 15 s by the luminometer.
The total protein concentration of the brain homogenates
was determined by a bicinchoninic acid (BCA) protein
assay kit (Thermo Fisher Scientific Inc., Rockford, IL) to
normalize luciferase activity.
Adoptive transfer
Translocation of immune cells into the CNS of animals
treated with or without morphine, HIV-1 Tat protein,
and S. pneumoniae was examined using adoptive transfer
experiment. HIV-1 Tat protein (10 μg/kg) [20, 22] was
given i.v. in age- and sex-matched donors, FVB/N lucifer-
ase transgenic mice (luciferase expression driven by the
β-actin promoter; Xenogen Corporation, Alameda, CA)
and recipient mice (B6CBAF1), after subcutaneous mor-
phine (25 mg) and placebo pellet implantation. Twenty-
four hours post pellet implantation, S. pneumoniae (1 ×
103 CFUs/500 μl) was given i.p. The spleens were aseptic-
ally removed from FVB/N luciferase transgenic mice at
day 4 and splenocytes were adoptively transferred into
wild-type mice as described elsewhere [24]. Briefly, the
harvested spleens were homogenized and red blood cells
were lysed using ammonium chloride lysing reagent.
Mixed luciferase-positive immunocytes (1 × 107 cells per
mouse) were transferred via tail vein injection into the
recipient mice at day 4. After 24 h, luciferase substrate
(D-luciferin, 150 μg, Gold Biotechnology, St. Louis, MO)
was administered by i.p. injection, mice were imaged using
Xenogen’s IVIS CCD camera system, and data were ac-
quired using a 5-min exposure window. The total photon
emission of each mouse was quantified as described in the
“Bioluminescence imaging and bacterial translocation”
section. Further, luciferase activity in brain tissues was
measured as described in the “Luciferase activity” section.
Immunohistochemistry
Prefrontal cortex (PFC) brain regions perfused with ice-
cold PBS were divided into three different tissue sections
and snap frozen in liquid nitrogen for different experi-
ments, confocal imaging, RT-PCR, and Western blot. In
HIV/AIDS infection, the PFC is especially important; it
undergoes disease-associated changes in synaptic tone
that produce abnormal neurocognitive phenotypes whichstrongly resemble many of the behavioral anomalies that
occur in HAND [25–27]. For immunohistochemistry ex-
periments, brain coronal cryostat (Leica Microsystems
Inc., IL) sections (5 μm) were prepared from groups of
snap-frozen brain tissue. For intracellular immunostain-
ing, cryostat tissue sections were fixed with 4 % parafor-
maldehyde, then permeabilized with 0.2 % PBS-Triton X,
and blocked with PBS-BSA (5 %) [25–27] for 1 h at room
temperature. Slides were washed with PBS-Tween (PBS-T;
0.02 %) and subsequently stained with required antibodies.
To identify the cellular or acellular mode of S. pneu-
moniae trafficking into the CNS, confocal microscopy
was used. Mouse anti-CD45, anti-CD3, and anti-Ly6C
(BD Biosciences; dilution 1:500) and rabbit anti-S. pneu-
moniae (Serotec; dilution 1:500) were used as primary
antibodies. Alexa Fluor 488-conjugated anti-mouse IgG
(Invitrogen; dilution 1:1000) and Rhodamine Red goat
anti-rabbit IgG (Jackson ImmunoResearch Laboratories;
dilution 1:1000) were used as secondary antibodies.
Chemokine ligands (CXCL12 and CCL5) and their co-
localization with glia, astrocytes, and microglia were also
observed using confocal microscopy. Mouse anti-CCL5
and mouse anti-CXCL12 were used as primary anti-
bodies (eBioscience; dilution 1:200), and Alexa Fluor 488-
conjugated anti-mouse IgG (Invitrogen; dilution 1:1000)
was used as a secondary antibody. To identify glia, Alexa
Fluor 555-conjugated glial fibrillary acidic protein anti-
body (GFAP; Cell Signaling Technology; dilution 1:1000)
was used as an astrocyte marker and rabbit anti-ionized
calcium-binding adapter molecule 1 (IBA-1; Wako, CA;
dilution 1:200) was used as a microglia marker. Rhoda-
mine Red goat anti-rabbit IgG was used as a secondary
antibody for microglia detection (Jackson ImmunoRe-
search Laboratories).
After staining with specific antibodies, tissues were
washed with PBS-T and mounted using ProLong Gold anti-
fade reagent with 4′,6′-diamidino-2-phenylindole (DAPI;
nuclei marker; Invitrogen; dilution 1:5000) and dried over-
night in the dark. Immunofluorescence images were ob-
tained on a Nikon Eclipse Ti confocal microscope using
a ×60 oil immersion objective. Sectioning was performed
on a minimum of five random sections from each of six in-
dividual mice per experiment.
Isolation of brain leukocytes and flow cytometry
For immunophenotyping of brain-infiltrated leukocytes,
we used flow cytometry. At the end of the treatment
period, mice were lethally anesthetized using CO2 as-
phyxiation and the brains were removed after being cardi-
ally perfused with ice-cold PBS as described in the
“Luciferase activity” section. Brain tissue was cut into
small pieces and enzymatically digested using collagenase
(Liberase, Roche) and single-cell suspension separated by
conventional 40/70 Percoll centrifugation. Mononuclear
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CD16/CD32 (2.4G2) (BD Biosciences) for 10 min at 4 °C
to reduce the nonspecific binding to the Fcγ receptor. Cells
were subsequently incubated for 30 min at 4 °C with
monoclonal antibodies (10 μg/ml) ACPCy7-CD45 (30-
F11), PECy7-CD11b (M1/70), PerCP-CD3 (145-2C11), and
phycoerythrin-conjugated Ly6C (AL-21) (all from BD
Biosciences).
To detect chemokine receptors on CNS immune cells,
we used biotinylated CCR5 (C34-3448) and CXCR4
(2B11/CXCR4) antibodies (10 μg/ml) as primary anti-
bodies; the secondary antibody was streptavidin conju-
gated with PerCP/PE. To stain TLRs on immune cells,
we used Alexa Fluor 488-conjugated anti-mouse TLR4
(UT41) and FITC-TLR2 (6C2) (eBioscience; dilution
1:200). The cells were washed twice and resuspended in
200 μl PBS with 0.1 % sodium azide. Dead cells were ex-
cluded by TROPO3 (Invitrogen) staining, and specific
isotype controls (BD Biosciences) were used in parallel.
Cells (10,000 events) were acquired using a FACSCanto
II cytometer, and data were analyzed using Diva software
(BD Biosciences).RT-PCR
Total RNA was extracted from frozen perfused brain tis-
sue using TRIzol reagent (Life Technologies, Carlsbad,
CA). RNA was reverse-transcribed using random hex-
amers from the TaqMan Reverse Transcription Reagents
and RT Reaction Mix (Applied Biosystems, Inc., Foster
City, CA) in a total volume of 40 μl at 25 °C for
10 min, at 42 °C for 30 min, and at 94 °C for 5 min on
a PCR machine (Mastercycler gradient, Eppendorf,
Germany). The resulting cDNA was used as a template
for RT-PCR. Specific oligonucleotide primer sequences
used in the amplification of chemokine ligand genes
were CCL5 and CXCL12 (Integrated DNA Technolo-
gies, Inc, Coralville, IA). Details of primer sequences
are given in Table 1. Real-time PCR was performed
using SYBR Green Master Mix (Applied Biosystems) on
the ABI Prism 7500 sequence detection system (Applied
Biosystems). 18S rRNA served as an internal control in
relative RT-PCR. The relative levels of chemokine ligands
in the brain homogenate were quantified using the ΔCt-
ΔCt method and were expressed as the percentage-fold
change.Table 1 Primers used for quantitative real-time RT-PCR
Primer Forward (5'–3') Reverse (5'–3')
CCL5 CCC TCA CCA TCA TCC TCA CT TCC TTC GAG TGA CAA ACA CG
CXCL12 TCA GTG GCT GAC CTC CTC TT TTT CAG CCA GCA GTT TCC TT
18S TTG ACG GAA GGG CAC CAC CAG CTC CTT AAT GTC ACG CAC GAT TTCWestern blot
Semi-quantitative estimation of CCL5 and CXCL12 che-
mokine ligand levels in the mouse brain was done using
Western blot. Proteins were harvested from frozen brain
tissues using RIPA cell lysis buffer (Biotech Corpor-
ation). The protein concentrations were measured by
using BCA protein assay kit. Equal aliquots of total
SDS-soluble proteins (100 μg) were resolved to 15 % dis-
continuous SDS-PAGE. The transferred nitrocellulose
membranes were blocked with 5 % fat-free milk in PBS-
T (blocking buffer) at room temperature for 1 h and
then incubated with primary antibodies (mouse anti-
CCL5 and rabbit anti-CXCL12 or anti-β-actin antibody
(eBioscience; 1:1000 dilution) at 4 °C overnight. After in-
cubating with primary antibodies, the membranes were
washed with PBS-T three times. Then the membranes
were incubated for 1 h with IRDye 800CW-conjugated
goat anti-rabbit IgG and IRDye 680-conjugated goat
anti-mouse IgG secondary antibodies (LI-COR Biosci-
ences, Lincoln, NE) diluted in blocking buffer. The blots
were then washed three times with PBS-T and rinsed
with PBS. Proteins were visualized by scanning the
membrane on Odyssey Infrared Imaging System (LI-
COR Biosciences) with both 700- and 800-nm channels.
ImageJ software was used to quantify the band intensity.
The protein levels of CCL5 and CXCL12 in the CNS
were represented by the ratios of optical densities in
their bands normalized against β-actin.
Statistical analysis
SPSS 16.0 statistical software was used for statistical
analysis. Data were collected from three independent
experiments and expressed as mean ± SEM. Statistical
significance was calculated by one-way ANOVA followed
by Bonferroni’s multiple-comparison test among different
groups. For correlation analysis, the Spearman rank order
correlation coefficient was used. Results were considered
significant at P≤ 0.05.
Results
Dissemination of S. pneumoniae into the CNS significantly
increased in morphine-treated mice exposed to HIV-1 Tat
protein
Several previous studies including ours have shown that
morphine-induced immunosuppression results in lack of
pathogen clearance in the infected animals [20, 23, 28, 29].
An increased pathogen burden results in their dissemin-
ation to various compartments, including the CNS.
In our current study, using real-time in vivo biolumines-
cent imaging of live mice infected with luciferase-tagged S.
pneumoniae (serotype 3), we showed a significant increase
in bacterial load when they were treated with morphine
alone. The effect was further exacerbated in mice treated
with both morphine and HIV-1 Tat. Increased bacterial
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severe bacteremia in the morphine-treated animals in the
presence or absence of HIV-1 Tat (Fig. 1a, b). The present
data is consistent with our previous findings, where we re-
ported that morphine treatment results in lack of bacterial
clearance when S. pneumoniae was administered intrana-
sally [20]. Current data in combination with the previous
observation suggest that bacterial inoculation given either
i.p. or intranasally results in a significant increase in bacter-
ial load in morphine-treated animals, despite the route of
infection.
Next, we investigated if the lack of bacterial clearance
increased bacterial trafficking into the CNS. PBS-perfused
mouse brains were aseptically dissected, and the intensity
of the luciferase signal was measured using Xenogen im-
aging. Placebo-treated mice efficiently cleared bacterial
infection from the periphery; however, in the morphine-
treated group, either in the presence or in the absence of
HIV-1 Tat, a significantly higher luciferase intensity was
observed in the brain, indicative of significantly greater
bacterial translocation into the CNS (Fig. 1c, d). To fur-
ther confirm that the photon emission by luciferase signal-
ing was CNS derived, PBS-perfused brains from the
respective groups were homogenized and the luciferase
activity of luciferase-tagged S. pneumoniae was evaluated
from the brain lysate using a luminometer. Morphine
treatment showed significantly higher luciferase activity in
the brain lysate which is further exacerbated with HIV-1
Tat (Fig. 1e).
Importantly, the synergistic increase in bacterial load
(Fig. 1f ) in the morphine-treated wt mice was signifi-
cantly attenuated in the morphine-treated MORKO mice
(Fig. 1c–e). These observations validate the significant
role of μ-opioid receptors in morphine-mediated bacter-
ial trafficking. Further, as expected, HIV-1 Tat-induced
bacterial trafficking into the CNS in the wt animals was
similar to that in the MORKO animals.Peripheral immune cell trafficking into the CNS
significantly increased in mice chronically treated with
morphine in the context of HIV-1 Tat and S. pneumoniae
Next, we investigated if peripheral immune cells in the
presence of morphine and/or HIV-1 Tat in the context of
secondary bacterial co-infection results in increased traf-
ficking. To test this hypothesis, an adoptive cell transfer
experiment was performed as described in the “Materials
and methods” section. The bioluminescence of adoptively
transferred luciferase-positive immune cells was signifi-
cantly higher both at the site of bacterial infection and in
the CNS of morphine- and/or HIV-1 Tat-treated wt mice
when compared to placebo-treated mice (Fig. 2a–e). Our
data strongly suggests that chronic morphine in the con-
text of systemic Gram-positive bacterial infection andHIV-1 Tat exposure induces significant migration of per-
ipheral immune cells into the CNS.
Cellular mode of S. pneumoniae trafficking into the CNS
of mice chronically treated with morphine and HIV-1 Tat
protein and infected with S. pneumoniae
Bioluminescence imaging of live animals and their re-
spective brains showed significantly higher bacterial load
with subsequent higher immune cell trafficking into the
CNS of mice treated with morphine and HIV-1 Tat and
co-infected with S. pneumoniae. Our results support the
proposed “Trojan horse” mechanism for the trafficking
of infected immune cells across the blood-brain barrier
(BBB) with subsequent release of pathogen within the
CNS [30, 31]. To determine if S. pneumoniae trafficking
into the CNS was occurring through infected peripheral
immune cells as a cellular mechanism or through direct
noncellular mechanism across endothelial cells, we in-
vestigated co-localization of S. pneumoniae with CD45+
antigen (leukocyte common antigen), a unique and ubi-
quitous membrane glycoprotein, expressed on almost all
hematopoietic cells except erythrocytes and platelets.
The presence of S. pneumoniae in the CNS of immune
cells was observed through immunohistochemistry of
brain tissue sections of animals treated with morphine,
HIV-1 Tat protein, and S. pneumoniae. Co-localization
of CD45+ immune cells with S. pneumoniae suggests a
cellular mode of bacterial trafficking into the CNS of the
treated mice (Fig. 2f ), and this observation supports a
Trojan horse mechanism for bacterial transmigration
through BBB in our model of systemic S. pneumoniae
infection.
Immunophenotyping of live CD45+ immune cells revealed
a significant increase in CD3+ and Ly6C+ immune cell
population in the CNS of treated mice
We observed differential leukocyte trafficking in the
CNS of mice following treatment with morphine, HIV-1 Tat,
and S. pneumoniae. Multicolor phenotypic characterization
of TOPRO3-CD45high-gated cells (live immune cells) re-
vealed ~3-fold increase in CD11b-CD3+ (T lymphocytes)
and ~6-fold increase in CD11b+Ly6C+ (inflammatory
monocytes) into the CNS of mice treated with HIV-1 Tat
alone (Fig. 3a (i), (iii) and Fig. 3b, c). Systemic bacterial
infection alone resulted in a significant increase of only
CD3+ lymphocytes (~3-fold) into the CNS of treated
mice. Chronic morphine does not induce any immune cell
trafficking by itself; however, in the presence of S. pneu-
moniae, it significantly upregulated the trafficking of T
lymphocyte (~5-fold) and inflammatory monocyte (~8-
fold) population into the CNS of treated mice (Fig. 3a (ii),
(iv) and Fig. 3b, c). Importantly, when all three treatment
groups were present, a robust infiltration of both popula-
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Fig. 1 Significant increase in bacterial translocation into the CNS of mice chronically treated with morphine and HIV-1 Tat and
co-infected with S. pneumoniae at the 5th day of post-pellet implantation. a Real-time in vivo bioluminescence imaging of
luciferase-tagged S. pneumoniae (serotype 3) administered (i.p.) in live wild-type (wt) and μ-opioid receptor knockout (MORKO)
mice chronically treated with morphine and HIV-1 Tat. b Histograms of mean bioluminescent signals from luciferase-tagged S.
pneumoniae quantified as total photon emission from treated live mice. c, d Bacterial translocation into the CNS was detected in
perfused mice brain using Xenogen’s IVIS CCD camera system, and total photon emission was quantified using Igor image analysis
software. e Luciferase activity was measured in the whole brain tissue dissected out from treated mice. Brain lysates were isolated by
homogenizing the brain tissue, and luciferase activity was measured using a luminometer, TD-20/20. Relative luminescence units (RLU)
were normalized with the Renilla luciferase values. f Histograms of mean bacterial counts in brain tissue. Error bars indicate the standard
error of the mean (SEM) of six different animals from each group (n = 6). Pseudocolor scales are shown to right of the figures. PP placebo
pellet, MP morphine pellet. *P < 0.05; **P < 0.01
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following systemic co-infection with S. pneumoniae result
in a dramatic trafficking of both inflammatory monocytes
and T lymphocytes into the CNS which may then contrib-
ute to unregulated inflammatory cytokine release which
can potentially damage healthy bystander brain cells and
disrupt CNS homeostasis as reported earlier [32–34].CXCR4 receptor expression on T lymphocytes and
inflammatory monocytes promoted their trafficking into
the CNS in morphine-treated mice exposed to HIV-1 Tat
and S. pneumoniae
To identify the specific mechanism for immune cell traf-
ficking into the CNS, we investigated the expression level of
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Fig. 2 Massive increase of immune cell trafficking into the prefrontal cortex of the CNS of mice treated with morphine and HIV-1 Tat and systematically
infected with S. pneumoniae at the 5th day of post-pellet implantation. a Splenocyte homing was assessed following the adoptive transfer of luciferase-
expressing immune cells (1 × 107) into B6CBAF1 recipient mice. The recipient mice were imaged for whole-body bioluminescence at 24 h following the
transfer of luciferase-positive immune cells. b The mean bioluminescent signal was measured as total photon emission using Igor image analysis software
as explained in Fig. 1b. c Immune cell homing in the perfused brain was assessed and d measured as explained in Fig. 1. e Luciferase activity in the brain
lysate was measured (indicative of the number of immune cells) and is presented as histograms of six different animals from each group.
Relative luminescence units (RLU) were normalized with the Renilla luciferase values. Error bars indicate the standard error of the mean (SEM)
of six different animals from each group (n = 6). Pseudocolor scales are shown to right of the figures. f Confocal microscopy and z-stacked
images showing CD45+ immune cells (Alexa Fluor 488-conjugated anti-mouse IgG; green) in the prefrontal cortex brain tissue with S. pneumoniae
(Rhodamine Red goat anti-rabbit IgG; red) and counterstained nuclei with DAPI (blue), suggesting cellular mode for bacterial translocation into the CNS
of mice treated with morphine and HIV-1 Tat and co-infected with S. pneumoniae. Merged images show co-localization of CD45+ immune cells and S.
pneumoniae. Magnification ×600 (upper panel) and ×2400 (lower panel). PP placebo pellet, MP morphine pellet. Scale bar 10 μm. *P < 0.05
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chemokine receptors, CCR5 and CXCR4, as these are
the co-receptors used for HIV-1 viral entry.
Systemic S. pneumoniae infection in the presence of
both morphine and HIV-1 Tat led to significant CXCR4
expression on CD3+ T lymphocytes which is consistentwith their migration pattern into the CNS (Fig. 3a, b),
suggesting that CXCR4 expression is involved in T cell
migration (Fig. 4a (i), (ii) and Fig. 4b). Interestingly,
although we did not observe significant trafficking of
CD3+ T lymphocytes into the CNS of morphine-treated
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Fig. 3 Significant trafficking of CD3+ and Ly6C+ immune cell population into the CNS of mice treated with morphine and HIV-1 Tat and co-infected with
S. pneumoniae (S.p) at the 5th day of post-pellet implantation. Single-cell suspension was isolated from the perfused brain of treated mice. Flow cytometry
analysis was performed to measure the frequency of TOPRO3-CD45highCD11b-CD3+ (T cells) and TOPRO3-CD45highCD11b+Ly6C+ (inflammatory
monocytes) in the CNS. a Representative dot plots demonstrating high influx of T lymphocytes and inflammatory monocytes into the CNS of
treated mice. The histogram represents quantification of specific immune cell (b CD3+; c Ly6C+) frequency as fold change from the group of untreated
mice [basal level (dashed line)] in the CNS. Error bars indicate the standard error of the mean (±SEM) of six animals in each group (n= 6 mice). PP placebo
pellet, MP morphine pellet. **P< 0.01
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quired for CCR5-induced trafficking might not be acti-
vated under these conditions (Fig. 5a (ii) and Fig. 5b).
Morphine treatment alone did not induce either traffick-
ing of the inflammatory monocytes or the expression of
CCR5 and CXCR4 (Figs. 4 and 5). However, significant traf-
ficking of the monocytic population was observed in the
presence of systemic infection with S. pneumoniae and/or
with HIV-1 Tat treatment with a concurrent increase in
CXCR4 expression. These data suggest that trafficking ofboth CD3+ T lymphocytes and inflammatory monocytes
mediated through CXCR4 and not through CCR5 recep-
tors. These data further suggest that systemic infection
might potentiate inflammatory monocyte trafficking
into the CNS of drug-dependent individuals (Figs. 4
and 5).
We show in Fig. 3 that HIV-1 Tat treatment alone re-
sults in significant trafficking of inflammatory mono-
cytes (~6-fold). In Fig. 4, we show a significant increase
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Fig. 4 Enhanced chemokine expression of CXCR4 on immune cells isolated from the perfused brain of mice treated with morphine, HIV-1 Tat,
and S. pneumoniae (S.p.) at the 5th day of post-pellet implantation. Flow cytometry profile of single-cell suspension. a Representative histograms
demonstrate CXCR4 expression on leukocytes isolated from the CNS of treated mice. Histograms demonstrating CXCR4 expression (i and ii) on
CD3+ and (iii and iv) on Ly6C+ cells. Bar diagrams representing quantification of CXCR4 expression on b CD3+ and c Ly6C+ cells as a mean fold
change from placebo control [basal level (dashed line)]. Error bars indicate the standard error of the mean (SEM) of six different animals from each
group (n = 6). PP placebo pellet, MP morphine pellet. *P < 0.05; **P < 0.01
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inflammatory monocyte trafficking. Importantly, treat-
ment of animals with all three insults, i.e., morphine,
HIV-1 Tat, and S. pneumoniae significantly upregulates
the expression of both CCR5 and CXCR4 on inflamma-
tory monocytes and on CD3+, indicating the participa-
tion of both receptors in the trafficking of peripheral
immune cells (Figs. 4 and 5).
S. pneumoniae used Ly6C+ cells as Trojan horse for
trafficking into the CNS
To characterize the specific immune cells which carry
pathogen across BBB into the CNS, perfused brain cryostattissue sections from mice chronically treated with mor-
phine, HIV-1 Tat protein, and S. pneumoniae were im-
munostained with specific cellular markers. We observed
co-localization of S. pneumoniae with inflammatory mono-
cytes (Ly6C+), suggesting the presence of intracellular bac-
teria in the monocyte population (Fig. 6). Positive staining
of CD3 antigen confirmed the presence of T lymphocytes
in the mouse brain. However, we did not observe co-
localization of S. pneumoniae with CD3+ T lymphocytes
(Fig. 6). The results suggest that dissemination of S. pneu-
moniae into the CNS is through a cellular mechanism and
mediated through a monocyte subset. Additionally, our
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Fig. 5 Enhanced chemokine expression of CCR5 on immune cells isolated from the perfused brain of mice treated with morphine, HIV-1 Tat, and
S. pneumoniae (S.p) at the 5th day of post-pellet implantation. Flow cytometry profile of single-cell suspension. a Representative histograms
demonstrating CCR5 expression on a distinct immune cell. Histograms demonstrating CXCR4 expression (i and ii) on CD3+ and (iii and iv) on
Ly6C+ cells. Bar diagrams representing quantification of CCR5 expression on b CD3+ and c Ly6C+ as a mean fold change from the group of mice
implanted with placebo pellets [basal level (dashed line)]. Error bars indicate the standard error of the mean (SEM) of six different animals from
each group (n = 6). PP placebo pellet, MP morphine pellet. *P < 0.05; **P < 0.01
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following S. pneumoniae, validating our finding of in-
creased cellular bacterial trafficking into the CNS (Fig. 3).
Systemic S. pneumoniae infection regulated TLR expression
in immune cell subtypes following morphine treatment
and in the context of HIV-1 Tat and S. pneumoniae
Activation of monocytes via TLR2 or TLR4 agonists
could differentially modulate immune cell chemokine
receptor expression and, therefore, potentially modulate
recruitment of specific immune cells [17, 35]. Our pre-
vious published data documented an increase in micro-
glial TLR (TLR2 and TLR4) surface expression in micetreated with morphine, HIV-1 Tat, and S. pneumoniae
[20]. Additionally, we reported significant attenuation
of the bacterial load into the CNS of TLRKO mice
treated similarly to wt mice, suggesting a crucial role of
TLRs in CNS leukocyte trafficking. Therefore, in the
present study, we investigated the role of TLRs in the re-
cruitment of immune cell into the CNS of mice treated
with chronic morphine and HIV-1 Tat following systemic
infection with S. pneumoniae.
In the presence of HIV-1 Tat and systemic S. pneumo-
niae co-infection, chronic morphine treatment resulted in
a significant increase in both TLR4 and TLR2 expressions




DAPI S. pneumoniae Merge
MergeS. pneumoniae
Fig. 6 Ly6C+ cells transport S. pneumoniae across the blood-brain barrier. Confocal microscope and z-stacked images of mouse prefrontal region
brain cryostat sections (5 μm) showing co-localization of immune cells, CD3+ and Ly6C+ cells (Alexa Fluor 488-conjugated anti-mouse IgG; green),
with S. pneumoniae. Merged images show co-localization of S. pneumoniae (Rhodamine Red goat anti-rabbit IgG; red) with Ly6C+ cells. Nuclei were
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Fig. 7 Differential surface expression of Toll-like receptors (TLRs) on
distinct immune cells at the 5th day of post-pellet implantation.
Histograms demonstrate mean fold change in TLR4 and TLR2 expression
on the CD3+ and Ly6C+ immune cells in the CNS prefrontal cortex
region of mice treated with morphine, HIV-1 Tat, and S. pneumoniae. Error
bars indicate the standard error of the mean (SEM) of six different
animals from each group (n= 6 mice). PP placebo pellet, MP morphine
pellet. *P< 0.05; **P< 0.01
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cantly upregulated (Fig. 7).
Trafficking of peripheral immune cells into the CNS was
TLR dependent
We next investigated if differential upregulation of TLRs
is responsible for the differential immune cell trafficking
pattern. A differential increase in TLR expression on im-
mune cells that trafficked into the CNS was observed in
groups of mice chronically treated with morphine and
HIV-1 Tat protein following infection with S. pneumo-
niae (Fig. 7). We evaluated the role of selective TLR acti-
vation in the trafficking of peripheral immune cells into
the CNS of the treated animals.
In the presence of HIV-1 Tat, morphine-induced CCR5
expression and S. pneumoniae-induced CXCR4 expression
on CD3+ T lymphocytes were downregulated only in the
TLR2KO mice. However, CXCR4 expression on inflam-
matory monocytes (Ly6C+) was dramatically downregu-
lated in both TLR2KO and TLR4KO mice with or without
chronic morphine treatment. These results implicate the
significant role of TLR2 in CD3+ cell migration and both
TLR2 and TLR 4 in the trafficking of inflammatory mono-
cytes (Fig. 8).
Chemokine ligands CCL5 and CXCL12 were significantly
upregulated in the CNS of mice chronically treated with
morphine and HIV-1 Tat and infected with S. pneumoniae
To determine if the cognate ligands for the upregulated
chemokine receptors (CCR5 and CXCR4) are also mod-
ulated in the brain tissues of mice treated with mor-
phine, HIV-1 Tat, and S. pneumoniae, protein as well as
























































Fig. 8 Differential trafficking of peripheral leukocytes with chemokine receptors (CCR5 and CXCR4) at day 5 into the CNS of wild-type (wt) and TLR
knockout (TLRKO) mice treated with morphine and HIV-1 Tat and systemically infected with S. pneumoniae. Histogram of percentage mean leukocyte
(CD3+ and Ly6C+) trafficking with CCR5 and CXCR4 into the CNS of wt and TLRKO mice. Error bars indicate the standard error of the mean (SEM) of six
different animals from each group (n = 6). PP placebo pellet, MP morphine pellet. *P < 0.05; **P < 0.01
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and CXCL12/SDF1 (stromal cell-derived factor-1) were
evaluated in brain homogenates [16].
Interestingly, HIV-1 Tat protein in the presence or ab-
sence of chronic morphine treatment significantly in-
duced CCL5 generation; however, synthesis of CXCL12
was specifically upregulated by bacterial treatment (Fig. 9).
Importantly, in the presence of all three insults, i.e., mor-
phine, S. pneumoniae, and HIV-1 Tat protein, a dramatic
increase in both ligands was observed. Importantly, CNS
ligand expression positively correlates with immune cell
(CD3+ and Ly6C+) trafficking into the CNS of treated
mice (Fig. 9e). In morphine-treated mice following HIV-1
Tat protein and S. pneumoniae infection, CCL5 expression
in the CNS resulted in significant trafficking of CD3+ and
Ly6C+ population (Fig. 9e (i), (ii)); however, CXCL12
expression correlates with trafficking of only Ly6C+ cells
(Fig. 9e (iv)). Data suggest that chemokine gradient facili-
tates a receptor-dependent trafficking of peripheral im-
mune cells into the CNS.
Furthermore, to confirm whether the decrease in per-
ipheral immune cells trafficking into the CNS of TLRKO
is associated with decrease in brain chemokine produc-
tion, immunoblotting of total protein isolated from the
brain tissue of wt, TLR2KO, and TLR4KO mice was per-
formed. We observed a significant decrease in CXCL12
synthesis in both TLR2 and TLR4KO mice; however, the
level of CCL5 was significantly lower only in the
TLR2KO mice (Fig. 9f ). Our data implicates that func-
tional TLRs are essential for chemokine ligand synthesis.
We previously documented that morphine in the presence
of S. pneumoniae and HIV-1 Tat protein increased TLR
expression on human cells as well as on murine microglial
cells [20]. Here, we established that upregulation of TLRexpression modulates chemokine production, thereby
generating a gradient for the trafficking of peripheral
immune cells with specific chemokine receptors into
the CNS.
Morphine treatment in the context of HIV-1 Tat and S.
pneumoniae infection increased chemokine ligand
(CCL5 and CXCL12) synthesis by microglial cells
To identify the cell type that produced the chemokine li-
gands, microglia cells were stained for IBA1 and astro-
cytes for GFAP and their co-localization with CCL5 and
CXCL12 evaluated. Results show that both the chemo-
kine ligands, i.e., CCL5 and CXCL12, co-localized with
IBA1 but not with GFAP, revealing microglia as the
major source of chemokine production in the brain tis-
sue of mouse treated with morphine, HIV-1 Tat protein,
and S. pneumoniae (Fig. 10).
Discussion
Opioid use and abuse accelerates HIV-1-associated
neurocognitive disorders (HAND) [36, 37]. Peripheral
leukocyte recruitment into the CNS has been impli-
cated in neuropathogenesis associated with neuroAIDS
[3, 8, 20, 32, 33, 38, 39]. However, the detailed mechan-
ism underlying this process is unclear. The exacerbated
induction of proinflammatory mediators from activated
leukocytes into the CNS through repetitive episodes of
systemic infection contributes to neurocognitive deficits
often observed in neurodegenerative diseases, such as
Alzheimer’s and Parkinson’s [5, 40, 41].
In the current study, we demonstrate that chronic ad-
ministration of morphine either independently or together
with HIV-1 Tat protein resulted in persistent bacterial in-
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Fig. 9 Chemokine ligand (CCL5 and CXCL12) production is significantly high in the prefrontal cortex region of mice chronically treated with
morphine, HIV-1 Tat, and S. pneumoniae. Histograms of differential mRNA expression of a CCL5 and b CXCL12 genes using 18S mRNA as
internal control in prefrontal cortex brain tissue isolated from the treated mice from all the groups. Histograms of band intensity of chemokine
protein synthesis of c CCL5 and d CXCL12 using ImageJ software. e Correlation analysis (R2) of CNS ligand (CCL5 and CXCL12) expression on
the y-axis with peripheral immune cell trafficking (i and iii) CD3+ and (ii and iv) Ly6C+ into the CNS (x-axis) of the wild-type animals treated
with chronic morphine, HIV-1 Tat, and S. pneumoniae. f Histograms of mean quantification of chemokine ligand CCL5 and CXCL12 generation
in the prefrontal cortex region of wild-type and TLR knockout mice. Error bars indicate the standard error of the mean (SEM) of six different
animals from each group (n = 6). PP placebo pellet, MP morphine pellet. *P < 0.05; **P < 0.01
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clearance and increased susceptibility to opportunistic in-
fection [42]. In addition, in our current study, we also de-
lineated the specific roles of morphine and HIV-1 Tat on
differential TLR expressions that contribute to distinct
leukocyte recruitment into the CNS following systemic
bacterial infection. We also demonstrate a Trojan horse
mechanism for bacterial dissemination across the blood-
brain barrier into the CNS by monocytes.
Morphine treatment results in attenuated bacterial
killing following S. pneumoniae infection. The regulatorymechanism associated with this outcome is either im-
paired TLR9-NF-κB signaling or blunted phagocytic prop-
erties of immune cells following exposure to morphine
[23, 43]. Compromised bacterial killing increased bacterial
load and resulted in persistent systemic infection. Mor-
phine induced inhibition of systemic bacterial clearance
leading to increased bacterial burden following their dis-
semination into the CNS which was significantly abolished
in the MORKO mice, suggesting that morphine-mediated
augmentation of S. pneumoniae infection was mediating
through μ-opioid receptors. Furthermore, in wild-type
CCL5 DAPI Merge
IBA-1 CXCL12 DAPI Merge
IBA-1





Fig. 10 Co-localization of chemokine ligands and microglia. Confocal microscope and z-stacked images of the prefrontal cortex brain tissue region
showing co-localization of chemokine ligands (Alexa Fluor 488-conjugated anti-mouse IgG; green): a CCL5 and b CXCL12 (Rhodamine Red
goat anti-rabbit IgG; red) with microglia (IBA+) rather than astrocytes (GFAP+). Counterstained nuclei of the cells with DAPI (blue). Magnification ×600.
Merged images present co-localization of glia (microglia or astrocytes) with chemokine ligand (CCL5 or CXCL12). Scale bar = 10 μm. Magnification of
the boxed area ×2400
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the CNS of mice treated with HIV-1 Tat alone. A possible
mechanism for the increased bacterial dissemination with
HIV-1 Tat-treated animals is significant disruption of
blood-brain barrier integrity following HIV-1 Tat treat-
ment, as reported earlier [44].
Furthermore, recent studies by Olin et al. [45] show
profound effects on splenocyte infiltration into the CNS
in an inflammation model in the presence of chronic
morphine. Their finding is consistent with our present
finding where we observed a significant infiltration of
peripheral immune cells into the CNS of animals treated
with morphine and/or HIV-1 Tat protein following sys-
temic infection with S. pneumoniae. The characterization
of phenotypic markers on live immune cells revealed a dif-
ferential influx of T lymphocytes (CD3+) and inflamma-
tory monocytes (Ly6C+) into the CNS. HIV-1 Tat alone
resulted in CNS trafficking of both CD3+ T lymphocytes
and Ly6C+ inflammatory monocytes. Surprisingly, sys-
temic bacterial infection resulted in dramatic trafficking
only of T lymphocytes. Although morphine treatment
alone did not alter the trafficking of any immune cell, we
observed robust and synergistic CNS trafficking of both Tcells and inflammatory monocytes when morphine-
treated animals were exposed to HIV-1 Tat and co-
infected with S. pneumoniae.
T lymphocytes are considered to be neuroprotective in
CNS damage, but their deleterious role in myelin deg-
radation in various autoimmune diseases has also been
reported [46, 47] through activation of inflammatory
cytokines such as IFN-γ and IL-17. We previously re-
ported that the synergistic effect of chronic morphine
with S. pneumoniae and HIV-1 Tat increased proinflam-
matory cytokine (TNF-α, IL-6, and MCP-1) synthesis in
the CNS [20]. We now demonstrate exacerbated T cell
and inflammatory monocyte recruitment into the CNS
following morphine, S. pneumoniae, and HIV-1 Tat treat-
ment, suggesting that migrated immune cells contribute
to the inflammatory milieu, disrupting CNS hemostasis,
eventually resulting in neuropathology.
The contributing role of chemokines and their recep-
tors in potentiating leukocyte trafficking during infection
is well documented. In the present study, we demon-
strated that HIV-1 Tat alone resulted in increased CCR5
expression on T lymphocytes with their subsequent traf-
ficking into the CNS. We further showed that systemic
Dutta and Roy Journal of Neuroinflammation  (2015) 12:120 Page 15 of 17bacterial infection modulated the trafficking of both T
lymphocytes and monocytes by activating the expression
of both CXCR4 and CCR5. However, the activation of
chemokine receptors alone is not sufficient for the mi-
gration of leukocytes. Rather, a highly regulated network
of chemokine gradient was needed for directing cell traf-
ficking. Exaggerated production in the microglia of the
cognate ligands (CXCL12 and CCL5) for the correspond-
ing chemokine receptors (CXCR4 and CCR5) provided
chemical gradients for attracting peripheral leukocytes to
the site of expression. Detailed analyses of our data re-
vealed that morphine induced an increase in CXCL12
generation in the presence of systemic infection. However,
the generation of CCL5 is predominantly a HIV-1 Tat ef-
fect. When all three insults are on board, a synergistically
increased production of both chemokine ligands in the
CNS resulted in a massive infiltration of activated periph-
eral immune cells into the brain. Excessive leukocyte re-
cruitment with surplus chemokine production in the CNS
has been shown to trigger neuronal injury and death via
overactivation of p38 MAPK [48].
Surprisingly, we found that chronic morphine, either
alone or with HIV-1 Tat, did not result in the trafficking
of any immune cells, even though it significantly increased
the surface expression of CCR5 on T lymphocytes. A po-
tential explanation lies in the heterodimerization and
cross-desensitization of the chemokine CCR5 receptor
with μ-opioid receptors in the presence of morphine,
which can alter the efficiency of ligand binding and signal-
ing, thereby contributing to decreased chemotaxis [49].
Moreover, it has been previously shown that CD3+ T
lymphocyte trafficking is mediated primarily through the
CXCR4 chemokine receptor [9]. In our study, morphine,
primarily, in the presence of HIV-1 Tat downregulated
both CXCR4 expression and the production of its cognate
ligand, CXCL12, in the CNS, thereby explaining the de-
creased T cell trafficking into the CNS, although the ex-
pression of CCR5 and its cognate ligand was high.
Numerous studies including ours have suggested that
morphine modulates various intracellular signaling ele-
ments of TLR pathways or directly binds to MD-2, thereby
inducing TLR4 oligomerization and activating TLR4 sig-
naling [20, 50, 51]. We previously demonstrated that mor-
phine potentiated TLR2 and TLR4 expression on
microglial cells leading to significant induction of proin-
flammatory cytokines with a concurrent increase in react-
ive oxygen species, nitric oxide production, and caspase-3
activation, thereby contributing to neuronal damage [20].
In the current study, we demonstrated that chronic mor-
phine in the presence of HIV-1 Tat and S. pneumoniae re-
sulted in TLR2 activation on T lymphocytes (Fig. 7).
However, we observed induction of both TLR2 and TLR4
on inflammatory monocytes. Activated TLRs induce up-
regulation of proinflammatory transcription factors (e.g.,NF-κB, activator protein 1 (AP-1), signal transducer
and activator of transcription (STAT)) which drives
promoters of proinflammatory cytokines and chemo-
kines that play a critical role in the pathophysiology of
neuroAIDS [18, 19, 52].
To the best of our knowledge, the present study is the
first to clearly demonstrate the distinct role of TLRs in
chemokine-induced peripheral leukocyte trafficking into
the CNS of HIV-infected opioid-dependent animals par-
ticularly in the presence of systemic pneumonia infec-
tion. Data shows that chronic morphine treatment in the
presence of HIV-1 Tat resulted in significant CNS traf-
ficking of Ly6C+CCR5+ and Ly6C+CXCR4+ following
co-infection with systemic S. pneumoniae infection, an
effect that was significantly attenuated in both TLR2KO
and TLR4KO mice. Significantly less monocyte (the bac-
terial transporters) trafficking into the CNS results in re-
duced S. pneumoniae dissemination into the CNS of
TLR2KO and TLR4KO mice as reported previously [20].
Further, the generation of cognate chemokine ligands
CCL5 and CXCL12 is significantly attenuated in both
TLR2KO and TLR4KO mice. HIV-1 Tat treatment acti-
vates TLR2 induction of CCL5 ligand and mediates the
CNS trafficking of CD3+CCR5+ T lymphocyte. Till date,
HIV-1 Tat protein is reported to activate TLR4 on mono-
cytes which contribute to abnormal hyper-activation of the
immune system via TNF-α production [53]. The present
investigation suggests that TLR2 activation by HIV-1 Tat
on T lymphocytes might also play a significant role. Fur-
ther, TLR2 signaling upregulates T cell infiltration and
microglial expansion through the MyD88-dependent path-
way [35].
Taken together, our study shows that chronic mor-
phine treatment results in significant upregulation of
TLR2 and TLR4 expression, both on peripheral immune
cells and on microglia. Subsequent activation of TLRs by
HIV-1 Tat and/or S. pneumoniae in morphine-treated
mice results in upregulation of chemokine receptor ex-
pression on peripheral immune cells, with a concurrent
increase in their cognate ligand secretion by microglial
cells. A combination of receptor and ligand expression
in different compartments induces migration of periph-
erally activated peripheral leukocytes into the CNS. The
resulting exacerbated neuroinflammatory responses might
be a contributing factor in HIV-1-associated neuropatho-
genesis observed in the drug-abusing population that are
HIV positive. These results also indicate that systemic in-
fection with Gram-positive bacteria may potentiate neuro-
pathogenesis in this population. Therapeutic interventions
that target TLR activation could be targeted to mitigate
neuroinflammation associated with neuroAIDS.Competing interests
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